Lymepak Shortage: What Providers and Prescribers Need to Know in 2026

For clinicians managing early Lyme disease patients, the discontinuation of Lymepak (doxycycline hyclate, NDA 209844) represents an important workflow update rather than a clinical crisis. This article provides a comprehensive overview of what prescribers need to know, how to communicate the change to patients, and how to ensure uninterrupted access to doxycycline-based Lyme disease treatment.

Clinical Summary: What Has Changed

Lymepak, manufactured by Chartwell RX, LLC, received FDA approval in 2018 as a branded doxycycline hyclate 100 mg tablet specifically indicated for early Lyme disease (erythema migrans) due to Borrelia burgdorferi in adults and pediatric patients ≥8 years old weighing ≥45 kg. The brand has since been discontinued. All Lymepak formulations — both the 14-tablet blister card (NDC 72135-596-86) and the 42-tablet carton (NDC 72135-596-87) — are no longer manufactured.

Critically, the active ingredient — doxycycline hyclate 100 mg — remains widely available in generic formulations from multiple manufacturers. There is no FDA-listed shortage of generic doxycycline hyclate as of 2026.

Prescribing Guidance: What to Write on the Prescription

To avoid patient confusion and pharmacy delays, update your prescription template from "Lymepak" to "doxycycline hyclate 100 mg tablets." The recommended prescribing language:

Drug name: Doxycycline hyclate 100 mg tablets

Sig: Take one tablet by mouth every 12 hours for 21 days

Quantity: 42 tablets

Refills: 0 (one-time course)

If your EHR system still has Lymepak as an active drug in the formulary, flag it for update. Prescriptions written for Lymepak may be filled generically by the pharmacist without issue (unless DAW is indicated), but writing generically from the outset reduces friction for the patient.

When to Consider Alternative Antibiotics

Doxycycline remains the preferred first-line antibiotic for early Lyme disease in most patients. However, the following populations require alternative agents:

Children <8 years old or weighing <45 kg: Use amoxicillin 50 mg/kg/day divided three times daily (max 500 mg/dose) for 14–21 days. Avoid doxycycline due to risks of permanent tooth discoloration and bone growth inhibition.

Pregnant patients: Doxycycline is not recommended during pregnancy (risk of tooth discoloration and inhibition of bone growth in the fetus). Use amoxicillin 500 mg three times daily for 14–21 days.

Tetracycline-allergic patients: Cefuroxime axetil 500 mg twice daily for 14–21 days. Monitor for penicillin cross-reactivity if applicable.

Advanced neurologic/cardiac disease: Ceftriaxone 2 g IV once daily. Oral doxycycline is not appropriate for CNS or significant cardiac Lyme disease.

Key Drug Interactions to Counsel Patients On

When prescribing generic doxycycline hyclate, counsel patients on these significant interactions:

Antacids, calcium, dairy, and iron supplements: Divalent cations significantly reduce doxycycline absorption. Advise patients to separate intake by at least 2 hours.

Warfarin and anticoagulants: Doxycycline depresses prothrombin activity. Monitor INR carefully and adjust anticoagulant dosing as needed.

Isotretinoin: Both drugs increase the risk of intracranial hypertension (pseudotumor cerebri). Avoid concurrent use.

Oral contraceptives: May reduce efficacy. Advise backup contraception.

Penicillins: Bacteriostatic doxycycline may antagonize bactericidal penicillins. Avoid co-administration.

38,404+ patients found their medications in stock

38K+

Find Lymepak In Stock Today →

The Jarisch-Herxheimer Reaction: Counseling Patients

One of the most clinically important counseling points unique to Lyme disease treatment is the Jarisch-Herxheimer (JH) reaction. This self-limiting systemic reaction occurs in up to 30% of patients with early Lyme disease treated with doxycycline. It presents as a transient worsening of symptoms — fever, chills, myalgia — occurring within the first 24–48 hours of antibiotic initiation.

Counsel patients proactively: the JH reaction is not an allergic reaction or treatment failure — it is a sign that the antibiotic is killing Borrelia bacteria. Advise patients to continue treatment and use supportive care (NSAIDs, hydration, rest). If symptoms are severe or the patient is concerned, they should call their provider.

How medfinder Can Help Your Patients Access Their Prescription

If your patients are having difficulty locating doxycycline hyclate at their local pharmacy — which can happen in areas with limited pharmacy options — medfinder for providers can help. medfinder contacts pharmacies in the patient's area to identify which ones can fill the prescription, then texts results directly to the patient. This removes the burden from your staff and helps ensure timely treatment initiation for Lyme disease.

Skip the calls, skip the stress.

Find Lymepak In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Clinical Takeaways for 2026

Update prescriptions from 'Lymepak' to 'doxycycline hyclate 100 mg tablets, 42 tabs, one tab PO BID x21 days'

Counsel patients that generic doxycycline hyclate is equally effective and significantly more affordable

Counsel all Lyme disease patients about the Jarisch-Herxheimer reaction proactively

Prescribe amoxicillin or cefuroxime for children <8 years, pregnant patients, or tetracycline-intolerant patients

Review for major drug interactions, particularly anticoagulants, antacids, and isotretinoin